patients in our cohort (n¼285,70%) had a "low risk" index while 14% (n¼57) had a "high risk" index. Of the remaining 16% of pregnancies with an "intermediate risk" index, 59% were complicated by fetal overgrowth. CONCLUSION: Despite substantial differences between the development and validation cohorts, both the previously published index and a parsimonious 3-variable derivative index proved predictive of fetal overgrowth in pregnancies complicated by diabetes. The index may serve as a tool for targeting the allocation of healthcare resources and treatment individualization, prior to the period of maximal fetal growth velocity in the third trimester.
OBJECTIVE:
To compare neonatal outcomes and assess the costeffectiveness of insulin therapy versus glyburide therapy in women with gestational diabetes in the context of most recent randomized controlled trials. STUDY DESIGN: A cost-effectiveness model using TreeAge software was designed to compare neonatal outcomes following insulin and glyburide management of gestational diabetes. A theoretical cohort of 195,000 women was used with assumed complete medication adherence. Outcomes included treatment method, mode of delivery, shoulder dystocia (SD), permanent brachial plexus injury (BPI), respiratory distress syndrome (RDS), neonatal hypoglycemia, macrosomia (>4000g), and neonatal hyperbilirubinemia. Probabilities were derived from the literature comparing insulin versus glyburide. Costeffectiveness was assessed by comparing cost of assessed outcomes with both neonatal and maternal quality-adjusted life years (QALY), with a cost-effectiveness threshold set at $100,000/QALY.
RESULTS:
Insulin was cost-effective in the management of women with gestational diabetes compared to glyburide. Insulin therapy resulted in 2,295 fewer cases of macrosomia, 386 fewer cases of cesarean deliveries, 12 fewer cases of shoulder dystocia, and 7,235 fewer cases of neonatal hypoglycemia despite an increased cost (Table 1) . There was no difference in cases of permanent brachial plexus injuries. Utilizing insulin therapy resulted in 1,858 more QALYs, with an incremental cost-effectiveness ratio (ICER) of $17,622/QALY. Univariate sensitivity analysis demonstrated that varying the compliance of insulin and glyburide simultaneously did not change the cost-effectiveness (Figure 1) . CONCLUSION: Using our baseline estimates, insulin is cost-effective for the management of gestational diabetes. Providers should take this into account when determining the most appropriate treatment for their patients with A2 GDM. STUDY DESIGN: Retrospective cohort study of all pregnant women with pregestational DM at a single tertiary institution (1/03-1/17) whose pregnancies reached at least 20 weeks' gestation. The primary outcome was frequency of major or minor congenital anomalies as assessed by ultrasound, pathology, and newborn examination (excluding known aneuploidy). Periconception HbA1C, defined as HbA1C within three months of conception, was assessed as a continuous variable and by category (HbA1C 7.4%, 7.5 e 9.4%, 9.5 e 11.4%, and 11.5%). The association of HbA1C with anomalies was analyzed using bivariable and multivariable analyses. RESULTS: Of 416 eligible women with pregestational DM, 65.5% had type 2 DM and 29.8% were non-Hispanic black. Nearly 1 in 6 (16.5%) women had a fetal anomaly. The majority of anomalies (75.4%) were classified as major and almost half of those (47.4%) were cardiovascular. The median HbA1C of women with fetal anomalies was significantly greater than that of women without anomalies (8.2% vs. 6.6%, p<0.001). The adjusted odds of anomaly increased significantly with each percentage point increase in HbA1c (aOR 1.47; 95% CI 1.27-1.69). Women with HbA1C 11.5% had a nearly 45% frequency of any anomaly ( Figure) and significantly increased adjusted odds of anomalies compared to women with HbA1c 7.4% (Table) . Women with HbA1C 7.5-9.4% and 9.5-11.4% also demonstrated similarly high frequencies of anomalies (19.7% and 33.3%, respectively) (Table) . Compared to women with the HbA1C 7.4%, women with HbA1C 11.5% were significantly more likely to be younger (RRR 0.92, 95% CI 0.85-0.99) and nonHispanic black (RRR 13.23, 95% CI 2.66-65.80). CONCLUSION: In a diverse cohort of women with pregestational DM, higher periconception HbA1C is significantly associated with congenital fetal anomalies. The frequency of anomalies is higher than reported in older literature, and identified to be as high as nearly 1 in 2 women with the poorest glycemic control.
Early hemoglobin A1c as a screening test for gestational diabetes among overweight and obese women
Amy Caldwell, Annessa Kernberg, Amy Valent, Kyle Hart Oregon Health and Science University, Portland, OR OBJECTIVE: Overweight and obese pregnant woman are known to be at increased risk of developing gestational diabetes. However, little is known about early screening in this population. The objective of this study was to determine early (< 20 gestational age) hemoglobin A1c values between overweight and obese pregnant women who develop gestational diabetes (GDM) compared those who do not develop GDM. STUDY DESIGN: A case-control study comparing overweight and obese women with GDM to overweight and obese women without GDM (non-GDM) in a 3:1 ratio between 2011 and 2014 at Oregon Health and Sciences University to determine if early hemoglobin A 1C (HbA 1C ; obtained < 20 weeks gestational age) differs between the two cohorts. Chi squared, Pearson correlation, and Wilcoxon ranksum test were used to compare GDM and non-GDM pregnancies. Receiver Operating Characteristic (ROC) curve was analyzed to plot the true positive rate against the false positive rate for the different possible cut-points of early HbA 1C to predict the diagnosis of GDM among overweight and obese women. RESULTS: A total of 443 subjects were analyzed (n¼139 cases and n¼304 controls). Women with GDM were more likely to be nonwhite, older in age, multiparous and have a higher pre-pregnancy BMI (see Table) . Women with GDM had a significant difference in early HbA 1C compared to non-GDM pregnancies (5.6 and 5.3%, P<0.01). Early HbA 1C is more significantly correlated with GDM diagnosis than pre-pregnancy BMI (0.34 vs 0.13; p<0.01). The curve point at which the area under the ROC curve was maximized was an early HbA 1C of 5.6% with an AUC ¼ 0.725 (see Figure) . CONCLUSION: Overweight and obese women who develop GDM have significantly different HbA 1C than non-GDM pregnancies. The mean HbA 1C is lower than the American Diabetes Association definition for pre-diabetes. When using A1c as a screening tool, these data suggest lower cut-points should be considered among overweight and obese pregnant women to perform early diagnostic diabetes testing in pregnancy. However, further studies are needed to determine a reliable, predictive HbA 1C .
